参考文献/References:
[1] Gaidai O,Cao Y,Loginov S. Global cardiovascular diseases death rate prediction[J]. Curr Probl Cardiol,2023,48(5):101622.
[2] Cook SA,Schafer S. Hiding in plain sight:interleukin-11 emerges as a master regulator of fibrosis,tissue integrity,and stromal inflammation[J]. Annu Rev Med,2020,71:263-276.
[3] Morris JC,Neben S,Bennett F,et al. Molecular cloning and characterization of murine interleukin-11[J]. Exp Hematol,1996,24(12):1369-1376.
[4] Fung KY,Louis C,Metcalfe RD,et al. Emerging roles for IL-11 in inflammatory diseases[J]. Cytokine,2022,149:155750.
[5] Liu NW,Huang X,Liu S,et al. Elevated BNP caused by recombinant human interleukin-11 treatment in patients with chemotherapy-induced thrombocytopenia[J]. Support Care Cancer,2019,27(11):4293-4298.
[6] Sweeney M,O’Fee K,Villanueva-Hayes C,et al. Interleukin 11 therapy causes acute left ventricular dysfunction[J]. Cardiovasc Res,2024,120(17):2220-2235.
[7] Cong X,Tian B,Zhu X,et al. Interleukin-11 is elevated in patients with atrial fibrillation,correlates with serum fibrosis markers,and represents a therapeutic target for atrial fibrosis[J]. Cerebrovasc Dis,2023,52(5):575-586.
[8] Ye J,Wang Z,Ye D,et al. Increased interleukin-11 levels are correlated with cardiac events in patients with chronic heart failure[J]. Mediators Inflamm,2019,2019:1575410.
[9] Xu Y,Ye J,Wang M,et al. Increased interleukin-11 levels in thoracic aorta and plasma from patients with acute thoracic aortic dissection[J]. Clin Chim Acta,2018,481:193-199.
[10] Corden B,Lim WW,Song W,et al. Therapeutic targeting of interleukin-11 signalling reduces pressure overload-induced cardiac fibrosis in mice[J]. J Cardiovasc Transl Res,2021,14(2):222-228.
[11] Rosenbloom J,Macarak E,Piera-Velazquez S,et al. Human fibrotic diseases:current challenges in fibrosis research[J]. Methods Mol Biol,2017,1627:1-23.
[12] Meng XM,Nikolic-Paterson DJ,Lan HY. TGF-β:the master regulator of fibrosis[J]. Nat Rev Nephrol,2016,12(6):325-338.
[13] Chen Y,Wang L,Huang S,et al. Lutein attenuates angiotensinⅡ- induced cardiac remodeling by inhibiting AP-1/IL-11 signaling[J]. Redox Biol,2021,44:102020.
[14] Schafer S,Viswanathan S,Widjaja AA,et al. IL-11 is a crucial determinant of cardiovascular fibrosis[J]. Nature,2017,552(7683):110-115.
[15] Lim WW,Corden B,Ye L,et al. Antibody-mediated neutralization of IL11 signalling reduces ERK activation and cardiac fibrosis in a mouse model of severe pressure overload[J]. Clin Exp Pharmacol Physiol,2021,48(4):605-613.
[16] Hassani M,Mahdevar M,Peymani M. Exploring the role of interleukin 11 in cancer progression,patient survival,and therapeutic insights[J]. Mol Biol Rep,2024,51(1):461.
[17] Xu DH,Zhu Z,Wakefield MR,et al. The role of IL-11 in immunity and cancer[J]. Cancer Lett,2016,373(2):156-163.
[18] Ma J,Xie Y,Xu Y,et al. Neutralization of interleukin-11 attenuates silica particles-induced pulmonary inflammation and fibrosis in vivo[J]. J Environ Sci (China),2023,126:772-783.
[19] Sugamura K,Keaney JF. Reactive oxygen species in cardiovascular disease[J]. Free Radic. Biol. Med,2011,51(5):978-992.
[20] Adam O,Frost G,Custodis F,et al. Role of Rac1 GTPase activation in atrial fibrillation[J]. J Am Coll Cardiol,2007,50(4):359-367.
[21] Sawyer DB. Oxidative stress in heart failure:what are we missing?[J]. Am J Med Sci,2011,342(2):120-124.
[22] Zhang Z,Zhao L,Zhou X,et al. Role of inflammation,immunity,and oxidative stress in hypertension:New insights and potential therapeutic targets[J]. Front Immunol,2023,13:1098725.
[23] Schumacher D,Liehn EA,Nilcham P,et al. A neutralizing IL-11 antibody reduces vessel hyperplasia in a mouse carotid artery wire injury model[J]. Sci Rep,2021,11(1):20674.
[24] Widjaja AA,Singh BK,Adami E,et al. Inhibiting interleukin 11 signaling reduces hepatocyte death and liver fibrosis,inflammation,and steatosis in mouse models of nonalcoholic steatohepatitis[J]. Gastroenterology,2019,157(3):777-792.e14.
[25] Ng B,Dong J,D’Agostino G,et al. Interleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis[J]. Sci Transl Med,2019,11(511):eaaw1237.
[26] Brischoux-Boucher E,Trimouille A,Baujat G,et al. IL11RA-related Crouzon-like autosomal recessive craniosynostosis in 10 new patients:resemblances and differences[J]. Clin Genet,2018,94(3-4):373-380.
[27] Lear S,Tafi R,Di Biasio VA,et al. De novo discovery of cyclic peptide inhibitors of IL-11 signaling[J]. Bioorg Med Chem,2025,119:118017.
相似文献/References:
[1]白春兰,张军.正五聚蛋白-3:新型心血管病炎性标志物[J].心血管病学进展,2016,(1):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
BAI Chunlan,ZHANG Jun.Pentraxin-3: A Novel Inflammation Biomarker for Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(9):87.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.023]
[2]任茂佳,贺文帅,张琪,等.围绝经期对心血管疾病相关危险因素的影响[J].心血管病学进展,2019,(6):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
REN Maojia,HE Wenshuai,ZHANG Qi,et al.Effects of Perimenopause on Cardiovascular Risk Factors[J].Advances in Cardiovascular Diseases,2019,(9):911.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.018]
[3]尹琳 黄从新.JP2蛋白和心血管疾病的研究进展[J].心血管病学进展,2019,(7):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
YIN Lin HUANG Congxin.Research Progress of JP2 Protein and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1004.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.010]
[4]朱峰 汪汉 蔡琳.抗体与心血管疾病[J].心血管病学进展,2019,(7):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
ZHU FengWANG HanCAI Lin.Antibodies and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1007.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.011]
[5]邱明仙 王正龙 许官学.心肌肌球蛋白结合蛋白-C磷酸化与心血管疾病关系的研究进展[J].心血管病学进展,2019,(7):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
QIU MingxianWANG ZhenglongXU Guanxue.Research Progress of the Relationship Between Cardiac Myosin Binding Protein-C and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1015.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.013]
[6]姬楠楠 杨晓静 谢勇.单核细胞/高密度脂蛋白比值与心血管疾病的研究进展[J].心血管病学进展,2019,(7):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
JI Nannan YANG Xiaojing XIE Yong.Monocyte/High-density Lipoprotein Ratio and Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(9):1019.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.014]
[7]渠海贤 李涛 程流泉.人工智能在心脏磁共振成像中的应用进展[J].心血管病学进展,2019,(5):659.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.001]
[8]侯冬华 郝丽荣.长正五聚蛋白3在动脉粥样硬化和心血管疾病中作用研究的新进展[J].心血管病学进展,2019,(5):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
HOU Donghua H AO Lirong.The Study of Atherosclerosis and Cardiovascular Diseases with Pentapycin 3[J].Advances in Cardiovascular Diseases,2019,(9):805.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.035]
[9]张维 张恒 康品方.外泌体在心血管疾病中的研究进展[J].心血管病学进展,2019,(5):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
Zhang WeiKang Pinfang.Exosome in Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(9):818.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.038]
[10]韦莹 刘书旺 李蕾 崔鸣.生长分化因子-15在心房颤动中的研究进展[J].心血管病学进展,2019,(8):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]
WEI Ying,LIU Shuwang,LI Lei,et al.Growth Differentiation Factor-15 in Development of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2019,(9):1073.[doi:10.16806/j.cnki.issn.1004-3934.2019.08.001]